This is the official Google+ page for Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day.
Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies.
Teva's net revenues in 2014 amounted to $20.3 billion. For more information, visit www.tevapharm.com
Note to Users: This page is intended to provide news and updates about our company, and Teva reserves the right to delete any comments that it considers to be inappropriate, abusive or spam.
Adverse events for any of our products should be reported to: Safety.AE@teva.co.il
Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details may be found here: http://www.tevapharm.com/en-US/Pages/Contact-Us.aspx
“We are extremely pleased with our performance this quarter, which is truly the manifestation of our commitment to solidifying our foundation, driving organic growth and creating the most efficient operational network in the industry," stated Erez Vigodman, Teva President and CEO.
Read the full press release: http://www.tevapharm.com/news/?itemid=%7BD87D2E15-5538-47FF-8ACB-5392030889BC%7D
What ‘green’ business practices does Teva engage in to promote socially and environmentally responsible economic growth? Learn more here: http://csr-2013-reports.tevapharm.com/environmental_respon…/
Last week, the University of Zagreb Faculty of Science opened their doors to the community for an Open Chemistry Day. Our colleagues at PLIVA in Croatia helped to engage and inform students and other attendees about the wonderful world of science and chemistry, as well as sharing interesting facts about working at PLIVA (a member of Teva Group).
Siggi addressed both the MBA class and undergraduate business, pre-med, and engineering majors, speaking about why the generics industry is such an attractive field, and how Teva is leveraging this attraction.
Teva’s global specialty medicines business focuses on core therapeutic areas of the central nervous system (CNS) which includes MS, other neurodegenerative diseases and pain; respiratory; and commercial activities in oncology, women’s health and local brands in regions and markets around the world.
Learn more about all of our business areas: http://www.tevapharm.com/about/profile/who_we_are/
Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its first quarter 2015 results and overall business environment. A Question & Answer session will follow this discussion.
In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time):
United States 1-866-926-5708;
International +44(0) 1452 560304;
For a list of other international toll-free numbers, click here: https://events.webeventservices.com/teva/2015/04/30/dial-in_details.html
A live webcast of the call will also be available on Teva's website at: www.tevapharm.com. Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software.
Following the conclusion of the call, a replay of the webcast will be available within 24 hours on the Company's website. The replay can also be accessed until June 1, 2015, 10:00 a.m. ET by calling United States 1-866-247-4222; Canada 1-866-878-9237 or International +44(0) 1452 550000; passcode: 28107594.